OPENING OF A FINANCING ROUND OF 750,000 € PRESENTATION AT BARCELONA STOCK EXCHANGE Tuesday, March 27 at 5 pm  (Pg. de Gracia 19, Barcelona)

We founded AB-Therapeutics in November 2009 with the goal to build a biotechnology company focused on bringing innovative medicines to patients, helping them lead better lives. Our approach leverages scientific knowledge and development expertise to develop innovative human therapeutics to treat cancer and other indications with unmet medical needs. We are committed to developing medications designed to improve clinical outcomes through better efficacy and improved safety.

 

We currently focus our development efforts in lung and pancreatic cancer with a new therapeutic approach. We are developing a proprietary new drug class called Lipid Analogue Therapeutics, with drug candidates with excellent efficacy and safety profile by the oral route.

 

We partner with academic research groups and other biotechnology companies with the aim to develop breakthrough products. And we continuously look for new opportunities to establish successful development partnerships.

We welcome your interest in our company.
Sincerely,

Carles Domènech, PhD
Chief Executive Officer